Compare Walt Disney Co (DIS) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Walt Disney Co vs Mesoblast Limited — how do they compare? Walt Disney Co trades at $95.9 (market cap $166.48B), while Mesoblast Limited trades at $17.61 (market cap $2.12B). The key difference: Walt Disney Co is far larger — about 78.5× Mesoblast Limited's market cap, and Walt Disney Co pays a 1.56% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| DIS | MESO | |
|---|---|---|
Market Cap | $166.48B | $2.12B |
Volume | 7,546,013 | — |
Sector | Media | Technology |
52-Week High | $122.94 | $20.96 |
52-Week Low | $92.40 | $10.96 |
Enterprise Value | $208.16B | $2.13B |
Dividend Yield | 1.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Disney (DIS) trades at $95.87, up 0.25% with a P/E of 15.36 and strong earnings beats in recent quarters. The company shows robust fundamentals with $94.43B revenue and $12.40B net income in 2025, though technical indicators signal bearish momentum. Recent news highlights advertising opportunities with major events and regulatory challenges with the FCC.
Outlook remains positive with analyst consensus at $125.60 target, representing 31% upside. Key opportunities include sports broadcasting rights and theme park recovery, while risks involve box office performance and regulatory pressures. The stock offers value with improving profitability and strong cash flow generation.
MESO trades at $16.22, up 5.05% today, with a bullish technical outlook from moving averages but mixed oscillators. The company shows strong gross margins of 80.52% but remains unprofitable with a net income margin of -144.33%. Recent news highlights commercial progress, including Ryoncil revenue of $36 million in Q4 2026 and pivotal Phase 3 trial milestones for chronic low back pain.
The outlook is cautiously optimistic, driven by FDA-approved Ryoncil's revenue growth and pipeline advancements, but high valuation (P/S 30.52) and persistent losses pose risks. Analyst consensus leans buy (45.46%), yet investors face volatility from clinical trial outcomes and cash burn concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Walt Disney Co
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
